Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Our team

Meet our team at the booth #130 during the 11th Protein & Antibody Engineering summit, in Lisbon (Portugal), November 18-22th, 2019.

Talk and poster presentations

AUDITORIUM III/IV – Nov. 21 – 12:15 Luncheon Presentation I: Establishment of a CHO Transient Expression Platform for Bispecific Fusion Protein Developability Assessment

Thibaut Angevin, PhD, Pieris Pharmaceuticals GmbH

Pieris Pharmaceuticals’ proprietary molecules, the Anticalin® proteins, are small therapeutics derived from human lipocalins. They can be genetically linked to antibodies to generate different bispecific fusion proteins. Those proteins display different developability profiles. Pieris’ developability assessment platform has been established in order to screen bispecific constructs at an early stage, with an aim of identifying candidates that are best suited for advancement to stable cell line development or further optimization of such constructs.

Polyplus-transfection
57A.    Development of an Advanced CHO Cell Expression System for Increased Transient Protein Production; Presented by Cassie-Marie P.

Polyplus-transfection
105B.  Addressing Large-Scale Therapeutic Virus Production Using High Quality Grade PEI-Based Transfection Reagents; Presented by Jean-Thomas I.

Contact us

General information

The convention will take place at the Lisbon Congres Center:
Praça Indústrias 1, 1300-307 Lisboa, Portugal.